Hypokalaemia and xipamide SIR,-I read the paper entitled "Ventricular fibrillation induced by xipamide" (13 February, p 494) with great interest.
We published a paper from this department in 1981,1 in which we drew attention to the fact that xipamide, although a very effective antihypertensive agent, caused profound reductions in the serum potassium concentrations, which were potentially dangerous, and recommended that it should not be used for this purpose unless adequate potassium supplements were given at the same time.'
It is not clear to me, however, why the authors have included indapamide in their indictment of xipamide since their case report refers to a patient who was simply taking the latter drug and not the former. There Hypokalaemia, defined as a serum potassium of less than 3 4 mmol(mEq)/l, was noted at least once in 10 of these. In four, despite a strong suspicion, there was insufficient evidence to incriminate directly either drug. In six cases, however, two on indapamide and four on xipamide, the temporal relationships of changing serum potassium to modifications in drug therapy strongly suggest that these drugs do cause hypokalaemia. Indapamide. Patient 1 was referred when already taking indapamide 2 5 mg daily. The initial serum potassium was 2 9 mmol/l, and he was then put on potassium supplements (20 mmol/day). Indapamide and potassium supplements were continued for 22 months, and the mean serum potassium over this period was 3 18 (range 2 8-3 7) mmol/l. When both supplements and indapamide were stopped and chlorthalidone was substituted (without any added potassium) the serum potassium rose to 3 9 (range 3-6-4 2) mmol/l and has remained in this range since.
Patient 2 was hypokalaemic (2 9 mmol/l) on chlorthalidone. He was changed to indapamide 2 5 mg daily and was given 30 mmol/l of potassium supplements. Over the next 13 months while on this combination the mean serum potassium was 3 4 (range 2 4-4 4) mmol/l. Chlorthalidone alone was then reintroduced and given for nine months. Despite not receiving any additional potassium the mean serum concentration rose to 4 56 (range 4-1-5-2) mmol/l. At the end of this period, however, indapamide was reintroduced and the potassium fell to a mean value of 3 5 (range 3-1-4-2) mmol/l Thereafter, a change back to the conventional thiazide diuretic, bendrofluazide 5 mg daily, has been associated with a persistently normal serum potassium.
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